ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,481 to 2,500 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Cycloset vs Placebo: Subjects Experiencing Serious Adverse Events176 of 2,054

98 of 1,016

-1.1 points

-3.4 to 1.0

3,070NCT00377676

Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes

Cycloset vs Placebo: serious adverse events176 of 2,054

98 of 1,016

-1.1 points

-3.4 to 1.0

3,070NCT00377676

Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes

Ginkgo Biloba vs Placebo: Number of Participants With Incident Dementia277 of 1,545

246 of 1,524

1.8 points

-0.9 to 4.4

3,069NCT00010803

Ginkgo Biloba Prevention Trial in Older Individuals

Ginkgo Biloba vs Placebo: serious adverse events1,000 of 1,545

961 of 1,524

1.7 points

-1.7 to 5.1

3,069NCT00010803

Ginkgo Biloba Prevention Trial in Older Individuals

NOMAC-E2 vs NETA-EE: Number of Participants Who Experience at Least One Venous or Arterial Thrombotic/Thromboembolic Event0 of 2,465

1 of 604

-0.2 points

-0.9 to 0.0

3,069NCT01656434

Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)

NOMAC-E2 vs NETA-EE: serious adverse events20 of 2,465

8 of 604

-0.5 points

-1.8 to 0.3

3,069NCT01656434

Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)

Best Practice Clinic-Based Care vs Telehealth Care: serious adverse events29 of 1,646

34 of 1,422

-0.6 points

-1.7 to 0.4

3,068NCT02996565

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

Ferric Carboxymaltose vs Placebo: Number of Deaths131 of 1,532

158 of 1,533

-1.8 points

-3.8 to 0.3

3,065NCT03037931

Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study

Ferric Carboxymaltose vs Placebo: deaths from any cause354 of 1,532

367 of 1,533

-0.8 points

-3.8 to 2.2

3,065NCT03037931

Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study

Ferric Carboxymaltose vs Placebo: Number of Hospitalizations for Heart Failure297 of 1,532

332 of 1,533

-2.3 points

-5.1 to 0.6

3,065NCT03037931

Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study

Ferric Carboxymaltose vs Placebo: serious adverse events413 of 1,532

401 of 1,533

0.8 points

-2.3 to 3.9

3,065NCT03037931

Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study

COPE participants vs Non-COPE participants: deaths from any cause8 of 173

92 of 2,885

1.4 points

-0.9 to 5.7

3,058NCT03326206

Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program

COPE participants vs Non-COPE participants: serious adverse events2 of 173

3 of 2,885

1.1 points

0.2 to 4.0

3,058NCT03326206

Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program

Fluarix 50-64 Years Group vs Fluarix 65+ Years Group: deaths from any cause2 of 1,047

10 of 2,007

-0.3 points

-0.7 to 0.2

3,054NCT00377611

Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™

Fluarix 50-64 Years Group vs Fluarix 65+ Years Group: serious adverse events23 of 1,047

105 of 2,007

-3.0 points

-4.3 to -1.6

3,054NCT00377611

Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™

Phone Call Group (Intervention Arm) vs Usual Care Group (Control Arm): Mortality68 of 1,534

75 of 1,520

-0.5 points

-2.0 to 1.0

3,054NCT03050918

Discharge Follow-up Phone Call Program

Phone Call Group (Intervention Arm) vs Usual Care Group (Control Arm): deaths from any cause68 of 1,534

75 of 1,520

-0.5 points

-2.0 to 1.0

3,054NCT03050918

Discharge Follow-up Phone Call Program

Phone Call Group (Intervention Arm) vs Usual Care Group (Control Arm): Number of Participants With In-patient Re-admissions228 of 1,534

232 of 1,520

-0.4 points

-2.9 to 2.1

3,054NCT03050918

Discharge Follow-up Phone Call Program

Enhanced Treatment vs Current Practice: Number of Children With Fever Who Received Coartem (Artemether-lumefantrine)265 of 963

2,066 of 2,084

-71.6 points

-74.4 to -68.7

3,047NCT00513500

Zambia Integrated Management of Malaria and Pneumonia Study

Rivaroxaban 2.5 mg Twice Daily (BID) vs Acetylsalicylic Acid 100 mg Once Daily (OD): Number of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events80 of 1,519

74 of 1,518

0.4 points

-1.2 to 2.0

3,037NCT02293395

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=125"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=125

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00377676-0dfac83e",
        "title": "Cycloset vs Placebo: Subjects Experiencing Serious Adverse Events",
        "summary": "176 of 2054 against 98 of 1016; risk difference -1.1 points, 95% interval -3.4 to 1.0; NCT00377676, Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes",
        "record": "/library/comparisons/NCT00377676-0dfac83e",
        "nct_id": "NCT00377676",
        "kind": "outcome",
        "participants": 3070,
        "risk_difference": {
          "value": -0.010770227480084951,
          "lower": -0.03350515068102344,
          "upper": 0.010296708659199474
        },
        "group_1": "176 of 2,054",
        "group_2": "98 of 1,016",
        "difference": "-1.1 points",
        "interval": "-3.4 to 1.0",
        "trial_title": "Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes"
      },
      {
        "id": "NCT00377676-sae",
        "title": "Cycloset vs Placebo: serious adverse events",
        "summary": "176 of 2054 against 98 of 1016; risk difference -1.1 points, 95% interval -3.4 to 1.0; NCT00377676, Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes",
        "record": "/library/comparisons/NCT00377676-sae",
        "nct_id": "NCT00377676",
        "kind": "serious-adverse-events",
        "participants": 3070,
        "risk_difference": {
          "value": -0.010770227480084951,
          "lower": -0.03350515068102344,
          "upper": 0.010296708659199474
        },
        "group_1": "176 of 2,054",
        "group_2": "98 of 1,016",
        "difference": "-1.1 points",
        "interval": "-3.4 to 1.0",
        "trial_title": "Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=126",
  "request_id": "jifxY_rBVMp5oBZA"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?